Showing results (11-20 of 157) with videos related to
Sort By:
Pageof 16
Current Opinion in Rheumatology|December 14, 2005
Musculoskeletal manifestations and autoimmune diseases related to new biologic agentsBoulos Haraoui, Edward KeystoneSeminars in Arthritis and Rheumatism|November 16, 2013
Interstitial lung diseases induced or exacerbated by DMARDS and biologic agents in rheumatoid arthritis: a systematic literature reviewCamille Roubille, Boulos HaraouiTherapeutics and Clinical Risk Management|March 25, 2008
Etanercept in the treatment of rheumatoid arthritisBoulos Haraoui, Vivian BykerkThe Journal of Rheumatology|May 4, 2010
Methotrexate drug interactions in the treatment of rheumatoid arthritis: a systematic reviewJosiane Bourré-Tessier, Boulos HaraouiBest Practice & Research. Clinical Rheumatology|December 10, 2013
To screen or not to screen: how to find and identify very early arthritisEdith VilleneuveThe Journal of Rheumatology|January 6, 2006
Anti-infliximab antibodies in patients with rheumatoid arthritis who require higher doses of infliximab to achieve or maintain a clinical responseBoulos Haraoui, Louise Cameron, Michèle Ouellet, et al.The Journal of Rheumatology. Supplement|May 4, 2010
Optimizing use of tumor necrosis factor inhibitors in the management of immune-mediated inflammatory diseasesBrian Bressler, Boulos Haraoui, Edward Keystone, et al.Clinical Rheumatology|January 17, 2012
Managing cardiovascular risk in patients with chronic inflammatory diseasesBoulos Haraoui, Peter P Liu, Kim A PappThe Journal of Rheumatology|October 4, 2011
Safety and effectiveness of rituximab in patients with rheumatoid arthritis following an inadequate response to 1 prior tumor necrosis factor inhibitor: the RESET TrialBoulos Haraoui, Maria Bokarewa, Ian Kallmeyer, et al.Journal of Cutaneous Medicine and Surgery|September 27, 2013
Preparing for subsequent entry biologics in dermatology and rheumatology in CanadaKim Papp, Marc Bourcier, Vincent Ho, et al.Pageof 16